The Progenics Board of Directors unanimously recommends that shareholders vote "FOR" all of Progenics' highly qualified and engaged directors on the WHITE proxy card today. The full text of the letter follows: ACT TODAY - VOTE THE WHITE PROXY CARD FOR ALL PROGENICS' HIGHLY QUALIFIED & EXPERIENCED DIRECTOR CANDIDATES June 3, 2019 Dear Fellow Shareholder: Your Board of Directors and management team are committed to enhancing the value of your investment in Progenics, and we continue to make substantial progress in developing and commercializing innovative targeted medicines and artificial intelligence to find, fight and follow cancer. Over the past year, we have achieved significant milestones across our pipeline, including initiating the commercial launch of AZEDRA and moving PyL into a pivotal Phase 3 trial that in just a few months, if successful, will support a New Drug Application filing next year.